+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 40 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating TQB2934, a special antibody designed to target multiple myeloma, a cancer affecting plasma cells. This antibody binds to T cells and cancer cells to activate the immune system to attack the disease. The study is a Phase 1 clinical trial focusing on safety and the bodys handling of the drug in patients with malignant plasma cell tumors. The study involves giving TQB2934 as a subcutaneous injection at doses of 40mg or 60mg. Treatment cycles occur once weekly during the first three cycles, then every two weeks for cycles four to six. If patients achieve a partial remission or better after six cycles, dosing continues every four weeks. Each treatment cycle lasts 28 days. Participants will undergo various assessments including blood tests to measure drug levels and immune response over 120 hours after each dose. Researchers will monitor adverse events for up to 24 months and evaluate treatment responses such as remission rates and survival outcomes. The total study participation includes treatment and long-term safety follow-up lasting up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
14 locations
P

Actively Recruiting

Researchers are evaluating TQB2102 for injection, a new antibody-coupled drug that targets two different parts of the HER2 protein on tumor cells. This study focuses on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. The trial aims to assess the effectiveness and safety of TQB2102 combined with benmelstobart or penpulimab, with or without chemotherapy, in this patient group. This is a Phase II randomized study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive TQB2102 for injection and either benmelstobart or penpulimab, both given intravenously every three weeks. Chemotherapy is taken orally from Day 1 to Day 15 in each 21-day treatment cycle. There are three study groups, each involving different combinations and doses of TQB2102, benmelstobart, penpulimab, and chemotherapy. Treatment continues through multiple cycles as determined by the study protocol. During the study, participants undergo regular assessments including scans and tests to measure tumor response and disease progression. Researchers monitor outcomes like the objective response rate, progression-free survival, duration of response, overall survival, and any adverse events. The study includes follow-up periods to track safety and effectiveness, with an average observation of up to three years. Participants are closely monitored throughout the treatment and follow-up phases for their health and response to therapy.

Age: 18Years - 75YearsAll GendersPhase 2
39 locations
R

Actively Recruiting

This research aims to evaluate the effects of TQH3906 Capsules in adults with active Psoriatic Arthritis PsA. The study plans to enroll 156 participants to assess how different doses of TQH3906 compare to placebo in improving PsA symptoms at Week 12, focusing on the proportion of participants reaching a 20% improvement according to the American College of Rheumatology criteria. Participants will be randomly assigned to receive one of several oral treatments daily from Day 1 to Day 169. These include 24 mg or 16 mg doses of TQH3906 capsules, a placebo phase followed by TQH3906, or an active comparator, Tofacitinib Citrate tablets. The study uses a double-blind design to compare these treatments effects and safety. Throughout the study, participants will attend visits for assessments including the ACR improvement criteria at multiple time points up to Day 169. Blood samples will be collected to evaluate drug levels and immune markers, and safety will be monitored closely. The main outcome is the proportion of participants achieving ACR20 response at Week 12. The study duration extends up to November 2027, with detailed evaluations of drug effects and adverse events throughout.

Age: 18Years - 70YearsAll GendersPhase 2
44 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of TQB3019 capsules in adults with advanced malignant tumors. This Phase 1 clinical trial uses a single-center, open, non-randomized, single-arm design to study patients with recurrent or refractory hematological cancers. Participants must meet specific health criteria, including physical status and organ function, to join the study. Participants receive TQB3019 capsules orally once daily, with doses ranging from 25 to 600 mg depending on the group. The trial includes two phases dose escalation and dose expansion. Treatment cycles last 28 days, and dosing may be single or continuous. The study monitors various outcomes such as dose limiting toxicity, maximum tolerated dose, and recommended phase II dose, along with adverse events and response rates. During the trial, participants undergo regular assessments including pharmacokinetic sampling at multiple time points, evaluation of protein levels, and monitoring of adverse effects up to about three years. Researchers measure overall response rates, disease control, progression-free survival, and overall survival. Safety is closely tracked from the first dose until 28 days after the last dose or other anti-tumor treatments begin. The total study duration extends to approximately three years with ongoing follow-up.

Age: 18Years +All GendersPhase 1
15 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of Jitongning tablets in adults with active axial spondyloarthritis ax-SpA. The study aims to determine if Jitongning tablets can improve symptoms and functions better than a placebo. It also assesses the safety of the tablets in this patient population. The trial is a randomized, double-blind, placebo-controlled Phase III study sponsored by Tasly Pharmaceutical Group Co., Ltd.

Age: 18Years - 65YearsAll GendersPhase 3
10 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
E

Actively Recruiting

Researchers are studying the effects of anifrolumab in Chinese adults aged 18 to 70 with active moderate to severe systemic lupus erythematosus SLE. The study aims to describe clinical outcomes focusing on remission and evaluates a systematic approach to reduce glucocorticoid GC use to minimize exposure. This phase 3b, open-label, single-arm trial collects safety, efficacy, and patient-reported outcomes in this population following current standard-of-care guidelines. Participants will receive a fixed intravenous dose of anifrolumab administered via infusion pump over at least 30 minutes every 4 weeks for a total of 13 doses from Week 0 to Week 48, alongside their stable standard treatments, which may include glucocorticoids, antimalarials, or immunosuppressants. The dosing schedule requires at least 14 days between doses, with the primary evaluation taking place at Week 52. During the study, participants will undergo regular assessments including disease activity indices, joint and skin evaluations, laboratory tests, and quality-of-life questionnaires at multiple timepoints up to Week 52. Researchers will monitor remission rates, glucocorticoid tapering success, flare rates, immune markers, and safety parameters. The total study duration for each participant is approximately one year, with detailed evaluations to understand the treatments impact on disease control and steroid reduction.

Age: 18Years - 70YearsAll GendersPhase 3
74 locations
P

Actively Recruiting

Researchers are evaluating a new medicine called YL201 compared to the standard chemotherapy chosen by doctors in people with locally advanced or metastatic esophageal squamous cell carcinoma who have stopped responding to first-line treatment. The goal is to see if YL201 works better and is safer. The study is a large, randomized phase III trial involving multiple hospitals and also investigates how YL201 is processed in the body, immune reactions it might cause, and whether certain biological markers can predict its effects. Participants will be assigned to one of two groups one group receives YL201 alone, given as an intravenous infusion on the first day of each 3-week cycle. The other group receives a chemotherapy drug chosen by their doctor, which may be paclitaxel, docetaxel, or irinotecan, each given intravenously on specific schedules every 3 weeks. The study treatment continues as planned, with monitoring throughout the treatment period. During the study, participants will undergo regular evaluations including scans and laboratory tests to measure how well the treatments are working and to monitor side effects. The main outcome researchers will track is overall survival for up to about 36 months. They will also assess progression-free survival, response rates, duration of response, and adverse events during this time. The study will last until the end of 2028, with ongoing monitoring and data collection.

Age: 18Years +All GendersPhase 3
81 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler BDA MDI compared with an albuterol sulfate AS metered dose inhaler in symptomatic Chinese adults with asthma. This randomized, double-blind, Phase III study aims to reduce the risk of severe asthma exacerbations in participants who have had asthma diagnosed for at least 12 months and currently use maintenance therapies. The study involves about 1000 eligible participants randomly assigned to receive either BDA MDI 160180 mcg delivered as two actuations of 8090 mcg or AS MDI 180 mcg delivered as two actuations of 90 mcg. Both treatments are used as needed for asthma symptoms or before exercise. The trial includes a screening period lasting 14 to 28 days, followed by a treatment period of at least 24 weeks and up to 52 weeks, and concludes with a safety follow-up about two weeks after the last treatment visit. Participants will be assessed through various visits during the study, including evaluations of lung function, asthma control questionnaires ACQ-5 and ACQ-7, and monitoring of severe asthma exacerbations. The primary outcome is the time to the first severe asthma exacerbation over the treatment period. Secondary outcomes include the rate of exacerbations, steroid exposure, and patient-reported measures of asthma control and quality of life. Safety and adherence are closely monitored throughout the study duration.

Age: 18Years +All GendersPhase 3
102 locations

1-10 of 40

1